# Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

> **NCT06210360** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changhai Hospital** · enrollment: 134 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan liposome injection
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **DRUG:** LV

## Key facts

- **NCT ID:** NCT06210360
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210360, "Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06210360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*